Quality Control Unit

21 CFR 111.105 vests in the Quality Control unit the authority to approve or reject — and the requirement that those decisions be made by qualified personnel, in writing, and on the basis of objective evidence against established specifications. Subpart F of Part 111 (sections 111.105 through 111.140) elaborates the operational obligations: review of records before release, decisions on returned product, decisions on packaging and labelling operations, decisions on holds and quarantines, decisions on reprocessing and reworking, decisions on reserve samples, and decisions on responding to out-of-specification (OOS) results. The QC unit is the regulatory disposition authority for every cGMP-controlled object the firm produces.

FDA's expectation, drawn from both the regulatory text and consistent inspection-finding practice, is that QC personnel cannot report to (or be performance-managed by) the production manager whose lots they approve or reject. Independence does not require a separate corporate entity — small firms regularly designate a Quality Manager with a dotted line to production but a solid line to the firm's owner, GM or board. What FDA looks for is structural authority: can the QC unit reject a lot under commercial pressure and have that decision stick? If the answer is no — if the COO can overrule a QC reject without a documented, scientifically supported re-disposition by the QC unit itself — the firm fails the independence test, regardless of the org chart.

1. Approve / reject every component lot (dietary ingredient, packaging, label, other) against the component specification — §111.75 / §111.113.
2. Approve the Master Manufacturing Record before it is used to produce a batch — §111.205.
3. Approve the Batch Production Record before the batch is released — §111.255 / §111.260.
4. Approve / reject in-process material against in-process specifications — §111.110.
5. Approve / reject the packaged-and-labelled finished supplement against the finished-product specification — §111.70(e) + §111.123.
6. Disposition returned product — §111.503.
7. Disposition out-of-specification results, including any decision to re-test, reprocess, rework or recall — §111.113 / §111.515 / §111.553.
8. Approve the disposal or destruction of rejected material and of reserve samples at end of retention — §111.93 / §111.83 / §111.95.
9. Review and approve all written procedures (SOPs) used by the firm in cGMP activities — §111.103.
10. Investigate consumer complaints involving possible failure of the supplement to meet specifications — §111.560.

§111.13 requires that personnel performing QC functions have the education, training and experience to perform their assigned functions. There is no specific degree or certification required by regulation, but the firm must be able to demonstrate the qualification of each QC individual — typically through a documented job description with required skills, a documented training program, and ongoing competency demonstrations. For analytical-method execution, the qualification must be method-specific (an analyst qualified on HPLC vitamin-C assay is not automatically qualified on HPTLC botanical identity). For QC disposition decisions, the qualification must be evidenced by both technical training (specification understanding, regulatory framework) and the documented authority to make the disposition.

A receipt-to-release flow under Subpart F looks like this in a well-run supplement firm:

1. Receipt — receiving operator quarantines the lot, generates the inspection task, captures container condition, count and supplier CoA.
2. Sampling — qualified sampler pulls per the sampling SOP, records location, quantity and reserve quantity per §111.83.
3. Identity test — qualified analyst executes the validated identity method per §111.75(a)(1)(i) and §111.320 against the documented reference standard.
4. Other spec tests — assay, purity, microbial, heavy metals as required by the component specification.
5. Record review — designated QC unit reviewer cross-checks specification, test results, analyst sign, reference-standard validity, reserve adequacy.
6. Disposition — QC unit approver issues APPROVED or REJECTED with reason. Approved status releases the lot to consumable inventory; Rejected status drives §111.113 quarantine, supplier notification, possible return or destruction.
7. Production consumption — only Approved lots are pickable by the work order. Batch close generates the BPR for QC unit review under §111.260.
8. BPR review — QC unit reviews the complete BPR for completeness, in-process spec conformance, deviations and corrective actions before finished-product disposition under §111.123.
9. Finished-product disposition — release to distribution requires QC unit approval against the finished-product specification per §111.70(e).

Many small supplement firms (under 25 employees) operate with overlapping roles by necessity. FDA's posture is pragmatic but firm: overlap is permissible if the QC unit's authority and independence over the specific decisions it makes are documented and demonstrably operational. Common stable patterns: a Quality Manager with sole authority to approve / reject lots, performance-managed by the owner not by the COO; a contract QA / consulting QP who provides documented disposition review for batches above a complexity threshold; a clear separation between 'production may suggest disposition' and 'QC unit decides disposition with documented rationale'. What does not work: a single individual who signs as production and QC on the same record; QC sign-off back-dated to match a release date; an org chart that puts QC under production.

1. QC unit reports into production — structural independence failure.
2. QC personnel not qualified for the methods they sign off — no training or competency record on file.
3. BPRs released without documented QC review — release stamp present, review evidence absent.
4. OOS results re-tested into pass without §111.113 investigation.
5. Component lots released with no QC disposition record — released by production directly.
6. Returned product disposition decisions made by sales / customer service, not the QC unit.
7. SOP changes approved by the document owner alone without QC unit signature.
8. Reserve sample disposal before the retention period because QC unit was not consulted.

Searches like 'QC unit software dietary supplement', '111.105 compliance', 'separation of duties supplement manufacturing', 'QA disposition system supplement', 'electronic batch record release SOP' come from quality leaders building out a formal QC unit — typically after a first 483, after a contract-manufacturer customer audit, or after the firm crosses a headcount where informal disposition no longer works. The buying motion centres on role-based access control (operators cannot release lots), two-person e-signature flows (Part 11 §11.50 / §11.200), a disposition workflow per component / batch / returned-product / SOP, and an audit trail that proves the QC unit decided every cGMP disposition.

• QC Unit role — a first-class system role with the exclusive authority to approve / reject lots, batches, SOPs, returned product, reserve disposal and OOS dispositions. Operators and production roles cannot perform these actions.
• Two-person e-signature — every QC unit disposition supports the preparer + independent reviewer flow (Part 11 §11.200), with the two signatures coming from distinct user accounts.
• Disposition workflows — pre-built flows for component receipt, in-process release, finished-product release, returned-product, OOS, SOP approval, reserve-disposal; each enforces specification linkage and audit trail.
• RBAC — role definitions and SoD rules are configurable per tenant; an operator who is granted QC-unit privileges leaves a documented role-change audit trail.
• BPR review surface — finished BPRs route automatically to the QC unit queue; release requires the BPR to be complete, specs met (or OOS investigation closed) and the e-sig captured.
• Returned-product flow — RMAs surface in the QC unit queue with the original batch reserve sample and BPR one click away; disposition decision is captured against the original batch lineage.
• Audit-trail evidence pack — one-click render of every QC unit decision for a date range, with who / when / what / why, for inspection.
• Industry-aware UI — supplement workspaces surface '§111.105 QC Unit' language and the §111.113 reject flow; pharma workspaces surface §211.22 instead.